STAT6 and neoplasm: Sushrut Kamerkar (92) designed the engineered exosome delivering an antisense oligonucleotide (ASO) targeting STAT6 (exoASO-STAT6), which selectively targeted tumor macrophages and produced potent antitumor activity.